COMMUNIQUÉS West-GlobeNewswire

Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market
28/01/2026
Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company anticipates full data analysis by the end of March 2026; data to be incorporated [...]
Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies
28/01/2026
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials BOSTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Life Biosciences , Inc., (“Life Bio”) a [...]
Aeroflow Health Partners with Priority Partners, owned by Johns Hopkins Health Plans and the Maryland Community Health System, To Expand DME Access to Maryland Medicaid Members
28/01/2026
Medicaid members under Priority Partners will now have access to critical care supplies such as breast pumps, diapers, and CPAPs ASHEVILLE, N.C., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Aeroflow Health , a pioneering [...]
Bexorg Awarded Grant from The Michael J. Fox Foundation to Identify Translational Biomarkers for TRPML1-Targeted Parkinson’s Disease Therapies
28/01/2026
- TRPML1 is a promising target 1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in clinical studies - Bexorg will leverage its postmortem whole-human [...]
Medline to report fourth quarter and full year 2025 results on February 25, 2026
28/01/2026
NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A [...]
Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals
28/01/2026
Kennewick, WA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in innovative cancer treatment technologies, announces the issuance of U.S. Patent No. 12,521,452 B2 by the United States Patent and [...]
Genvor Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization
28/01/2026
Agricultural biologicals leader brings 15+ years of global R&D and product management experience from Syngenta to accelerate Genvor’s strategic partnerships and market expansion Woodland, CA, Jan. 28, 2026 (GLOBE [...]
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
28/01/2026
PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report [...]
Altanine Appoints Patrice Launay as Chief Financial Officer
28/01/2026
Seasoned public company finance executive brings deep expertise in SEC reporting, capital markets, and scaling high-growth companies LOS ANGELES, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Altanine , a specialty pharmaceutical [...]
HealthEdge® and Suki Introduce Ambient Clinical Intelligence for Care Management
28/01/2026
Integration of Suki with HealthEdge GuidingCare® Delivers AI-Powered Automation That Reduces Administrative Burden for Care Managers and Elevates Care Quality BOSTON and REDWOOD CITY, Calif., Jan. 28, 2026 (GLOBE [...]
Confluent Medical Debuts Filmcast Select™ to Enable Tailored Performance in PTFE and Polyimide Tubing
28/01/2026
New Filmcast Select™ Program Allows OEMs To Tailor Flexibility, Strength, And Durability In PTFE And Polyimide Tubing To Meet The Demands Of Next-Generation Minimally Invasive Devices CHATTANOOGA, Tenn., Jan. 28, 2026 ( [...]
NetraMark Closes First Tranche of Private Placement
28/01/2026
TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a premier artificial intelligence (AI) company transforming clinical trials [...]
ENvue Medical Signs Strategic Partnership Agreement with U-Deliver for U.S. Distribution of Over-the-Counter Reusable ENFit Syringe Line
28/01/2026
Distribution agreement leverages U-Deliver’s digital and wholesale channels to expand access to ENvue’s recently launched ENFit Syringes across non-acute care channels TYLER, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- [...]
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
28/01/2026
This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutions JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- [...]
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
28/01/2026
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
28/01/2026
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB [...]
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
28/01/2026
Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses WASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees [...]
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
28/01/2026
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this [...]
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
28/01/2026
Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical Data MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE [...]

Pages